๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma
Clinical trial register · Taiwan

Diffuse Large B Cell Lymphoma Trials in Taiwan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Taiwan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2872 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2872
Studies in scope
all four open statuses
1562
Recruiting now
open to new participants
339
Lead sponsors
across recruiting studies
Top sites
Taipei 11 Tainan 11 Kaohsiung City 9 Taichung 4 Taoyuan City 2
Narrow the registerReset
Recruitment status
Phase
Site location
Taipei11 Tainan11 Kaohsiung City9 Taichung4 Taoyuan City2
All 15 locations
Target enrolment
to

Diffuse Large B Cell Lymphoma trials in Taiwan

14 of 2872 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Taiwan
Start
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Taipei
2024-08-16
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024Diffuse Large B-Cell Lymphoma
AstraZeneca
Phase 2
80
Kaohsiung City, Tainan, Taipei
2024-07-16
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Taichung, Taipei
2023-04-04
Recruiting
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
NCT05377307Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma Grade 3A
Pell Bio-Med Technology Co., Ltd.
Observational
49
Kaohsiung, Taipei, Tainan
2022-12-29
Recruiting
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
NCT05326243Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma, Follicular Lymphoma Grade 3A
Pell Bio-Med Technology Co., Ltd.
Phase 1/2
49
Taipei, Kaohsiung City, Tainan
2022-05-31
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Chang-hua, Chiayi City, Hualien City, Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei
2021-05-11
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
AstraZeneca
Phase 1
226
Kaohsiung City, Kweishan, Tainan, Taipei
2021-03-02
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
Genmab
Phase 3
483
Kaohsiung City, Tainan, Taipei
2021-01-13
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Kaohsiung City, Tainan, Taipei, Taoyuan City
2020-10-08
Active, closed
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283Diffuse Large B-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Taipei, Kaohsiung City, Tainan, Taoyuan
2020-08-20
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Taiwanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-taiwan/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Taiwan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,872 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Diffuse Large B Cell Lymphoma.

How many Diffuse Large B Cell Lymphoma trials are recruiting in Taiwan?

5 of the 14 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma), 14 studies
PhaseStudiesRecruitingShare
Phase 38157.1%
Phase 12014.3%
Phase 1/22214.3%
Observational117.1%
Phase 2117.1%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
Genmab30
AstraZeneca21
Merck Sharp & Dohme LLC22
Pell Bio-Med Technology Co., Ltd.22
AbbVie10
Acerta Pharma BV10
Hoffmann-La Roche10
Incyte Corporation10
Seagen, a wholly owned subsidiary of Pfizer10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.